Related Experiment Video
Updated: Apr 27, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
1.1K
Type-1 cannabinoid receptor activity during Alzheimer's disease progression
Iván Manuel1, Estíbaliz González de San Román1, M Teresa Giralt1
1Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Spain.
Journal of Alzheimer'S Disease : JAD
|June 21, 2014
Summary
Cannabinoid receptor 1 (CB1) activity initially increases in early Alzheimer's disease (AD) brain areas, suggesting a compensatory mechanism. This hyperactivity decreases in later stages, indicating disease progression may overcome the endocannabinoid system's attempts to heal.
Area of Science:
- Neuroscience
- Pharmacology
- Pathology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- The endocannabinoid system, including cannabinoid receptor 1 (CB1), plays a role in brain function.
- Synaptic impairment is an early feature of AD.
Purpose of the Study:
- To investigate the activity of CB1 receptors in postmortem brain samples from Alzheimer's disease patients.
- To understand the role of CB1 receptor activity in different stages of Alzheimer's disease progression.
Main Methods:
- Analysis of postmortem brain samples from Alzheimer's disease patients at various clinical stages.
- Measurement of CB1 receptor activity in specific brain regions, including the hippocampus and frontal cortex.
Main Results:
- CB1 receptor activity was elevated in earlier stages of AD, particularly in the hippocampus and frontal cortex.
- A decline in CB1 activity was observed in advanced stages of AD.
- The observed pattern suggests initial hyperactivity of the endocannabinoid system as a compensatory response to synaptic impairment in early AD.
Conclusions:
- The endocannabinoid system, via CB1 receptors, may attempt to compensate for early synaptic deficits in Alzheimer's disease.
- Disease progression eventually surpasses the compensatory capacity of the endocannabinoid system.
- Targeting CB1 receptors in the early stages of AD might offer therapeutic potential.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:22Dementia l: Introduction
31
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
31
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K